Bioxyne Limited (BXN) Price & Analysis

Q: What was Bioxyne Limited’s price range in the past 12 months?

Bioxyne Limited lowest share price was AU$0.02 and its highest was AU$0.06 in the past 12 months.

Q: What is Bioxyne Limited’s market cap?

Bioxyne Limited’s market cap is AU$92.21M.

Q: When is Bioxyne Limited’s upcoming earnings report date?

Bioxyne Limited’s upcoming earnings report date is Feb 19, 2026 which is in 61 days.

Q: How were Bioxyne Limited’s earnings last quarter?

Bioxyne Limited released its earnings results on Aug 29, 2025. The company reported AU$0.001 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.001.

Q: Is Bioxyne Limited overvalued?

According to Wall Street analysts Bioxyne Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Bioxyne Limited pay dividends?

Bioxyne Limited does not currently pay dividends.

Q: What is Bioxyne Limited’s EPS estimate?

Bioxyne Limited’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Bioxyne Limited have?

Bioxyne Limited has 2,195,428,700 shares outstanding.

Q: What happened to Bioxyne Limited’s price movement after its last earnings report?

Bioxyne Limited reported an EPS of AU$0.001 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -16.667%.

Q: Which hedge fund is a major shareholder of Bioxyne Limited?

Currently, no hedge funds are holding shares in AU:BXN

Compare

12 Followers

BXN Stock Chart & Stats

AU$0.04

<AU$0.01(4.17%)

At close: Jan 09 4:00 PM EST

AU$0.04

<AU$0.01(4.17%)

Day’s Range― - ―

52-Week RangeAU$0.02 - AU$0.06

Previous CloseN/A

Volume631.90K

Average Volume (3M)4.35M

Market Cap

AU$92.21M

Enterprise ValueAU$86.43M

Total Cash (Recent Filing)AU$7.67M

Total Debt (Recent Filing)AU$1.53M

Price to Earnings (P/E)17.5

Beta1.33

Next Earnings

Feb 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)<0.01

Shares Outstanding2,195,428,700

10 Day Avg. Volume2,483,521

30 Day Avg. Volume4,348,514

Financial Highlights & Ratios

PEG Ratio-0.13

Price to Book (P/B)7.54

Price to Sales (P/S)2.90

P/FCF Ratio22.82

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusModerate Buy

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bioxyne Limited News

Bioxyne Limited Announces Issuance of Unquoted Equity Securities

The latest announcement is out from Bioxyne Limited ( ($AU:BXN) ). Bioxyne Limited has announced the issuance of...

3d ago

BXN

Bioxyne Limited Announces Director’s Interest Change

The latest announcement is out from Bioxyne Limited ( ($AU:BXN) ). Bioxyne Limited announced a change in the...

6d ago

BXN

Bioxyne Limited Issues New Shares to Directors and Consultants

Bioxyne Limited ( ($AU:BXN) ) has issued an update. Bioxyne Limited has issued a total of 5,600,000 shares,...

6d ago

BXN

Bioxyne Limited Issues Shares to Settle Invoice

Bioxyne Limited ( ($AU:BXN) ) has shared an announcement. Bioxyne Limited has announced the issuance of 1,200,000 ordinary...

6d ago

BXN

Bioxyne Enters Central American Cannabis Market with Key Supply Agreement

An update from Bioxyne Limited ( ($AU:BXN) ) is now available. Bioxyne Limited has secured a manufacturing and...

10d ago

BXN

Bioxyne Limited Appoints New CFO to Drive Strategic Growth

Bioxyne Limited ( ($AU:BXN) ) has shared an update. Bioxyne Limited has appointed Mr. Paul Mitchell as the...

19d ago

BXN

Bioxyne Limited Successfully Passes All AGM Resolutions

The latest update is out from Bioxyne Limited ( ($AU:BXN) ). Bioxyne Limited announced that all resolutions were...

25d ago

BXN

Bioxyne Limited Reports Record Growth and Strategic Milestones at 2025 AGM

An announcement from Bioxyne Limited ( ($AU:BXN) ) is now available. Bioxyne Limited announced significant growth and strategic...

25d ago

BXN

Bioxyne Limited Advances MDMA-Assisted Therapy with Second Shipment for Clinical Trials

The latest update is out from Bioxyne Limited ( ($AU:BXN) ). Bioxyne Limited, through its subsidiary Breathe Life...

25d ago

BXN

Bioxyne Limited Launches Australian Made MDMA Capsules for PTSD Treatment

Bioxyne Limited ( ($AU:BXN) ) just unveiled an announcement. Bioxyne Limited, through its subsidiary Breathe Life Sciences, has...

1M ago

BXN

BXN FAQ

What was Bioxyne Limited’s price range in the past 12 months?

Bioxyne Limited lowest share price was AU$0.02 and its highest was AU$0.06 in the past 12 months.

What is Bioxyne Limited’s market cap?

Bioxyne Limited’s market cap is AU$92.21M.

When is Bioxyne Limited’s upcoming earnings report date?

Bioxyne Limited’s upcoming earnings report date is Feb 19, 2026 which is in 61 days.

How were Bioxyne Limited’s earnings last quarter?

Bioxyne Limited released its earnings results on Aug 29, 2025. The company reported AU$0.001 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.001.

Is Bioxyne Limited overvalued?

According to Wall Street analysts Bioxyne Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bioxyne Limited pay dividends?

Bioxyne Limited does not currently pay dividends.

What is Bioxyne Limited’s EPS estimate?

Bioxyne Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Bioxyne Limited have?

Bioxyne Limited has 2,195,428,700 shares outstanding.

What happened to Bioxyne Limited’s price movement after its last earnings report?

Bioxyne Limited reported an EPS of AU$0.001 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -16.667%.

Which hedge fund is a major shareholder of Bioxyne Limited?

Currently, no hedge funds are holding shares in AU:BXN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Bioxyne Limited Stock Smart Score

Outperform

Fundamentals

Return on Equity

61.21%

Trailing 12-Months

Asset Growth

192.29%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bioxyne Limited

Bioxyne Limited, a life sciences and health products company, researches, develops, markets, and distributes dietary supplement and beauty products. It perates in two segments, Wholesale Sales and Direct Sales. The company engages in developing various functional foods and beauty products. Its products portfolio includes Progastrim for Gut and Immune Health; Progastrim plus Vitamin C for cold symptoms; and proTract for atopic dermatitis (eczema) for infants. The company provides its products online, as well as through wholesale and direct sales in the United States and Asia. Bioxyne Limited was incorporated in 1998 and is headquartered in Sydney, Australia.